Ovarian ischemia-reperfusion injury (OIRI) causes oxidative damage, inflammation, and tissue destruction, frequently causing tissue damage and inflammation. Although G protein-coupled receptor 84 (GPR84) operates as a modulator of immune cell activation across numerous pathological contexts, its specific contributions to OIRI pathophysiology remain insufficiently characterized. We therefore examined whether pharmacological blockade of GPR84 confers protection against OIRI and delineated the operative signaling networks. Utilizing a murine model of bilateral ovarian ischemia followed by reperfusion, we administered either PBI-4050 or BGT-004 to evaluate therapeutic efficacy. Our analyses revealed pronounced GPR84 upregulation within ovarian tissues subjected to ischemic insult. Tissue fractionation experiments showed that GPR84 upregulation occurred predominantly in CD45⁺ leukocytes. Both antagonistic compounds substantially mitigated histological deterioration while attenuating lipid peroxidation (malondialdehyde accumulation), oxidative radical generation (nitric oxide), and neutrophil infiltration (myeloperoxidase activity), concomitantly enhancing antioxidant defense (superoxide dismutase function) and curtailing secretion of IL-1β and IL-18. Additionally, treatment suppressed NOX-4 expression and thwarted NLRP3 inflammasome assembly, reflected in diminished NLRP3 protein abundance and reduced caspase-1 cleavage. GPR84 blockade also reduced gasdermin D cleavage, indicating suppression of pyroptotic cell death. Mechanistically, GPR84 blockade reinstated AMPKα phosphorylation status and restored phosphorylation of the downstream AMPK substrate acetyl-CoA carboxylase; however, co-administration of the AMPK antagonist Compound C with BGT-004 nullified these protective actions, suggesting that AMPK signaling contributes to therapeutic efficacy. The Compound C mechanistic validation was performed using BGT-004, the selective GPR84 antagonist, to avoid confounding from PBI-4050's GPR40 agonist activity. These observations collectively suggest that GPR84 antagonism ameliorates OIRI through AMPK-dependent suppression of NLRP3 inflammasome activity, identifying this receptor as a candidate for further investigation in ischemia-reperfusion injury.